Sonali Palchaudhuri1, Hannock Tweya2, Mina Hosseinipour3. 1. Johns Hopkins Bayview Medical Center, Baltimore, MD, USA ; University of North Carolina Project, Lilongwe, Malawi. 2. Lighthouse Trust, Lilongwe, Malawi; 4University of North Carolina School of Medicine, Chapel Hill, USA. 3. University of North Carolina Project, Lilongwe, Malawi.
Abstract
BACKGROUND: The 2011 Malawi HIV guidelines promote CD4 monitoring for pre-ART assessment and considering HIVRNA monitoring for ART response assessment, while some clinics used CD4 for both. We assessed clinical ordering practices as compared to guidelines, and determined whether the samples were successfully and promptly processed. METHODS: We conducted a retrospective review of all patients seen in from August 2010 through July 2011,, in two urban HIV-care clinics that utilized 6-monthly CD4 monitoring regardless of ART status. We calculated the percentage of patients on whom clinicians ordered CD4 or HIVRNA analysis. For all samples sent, we determined rates of successful lab-processing, and mean time to returned results. RESULTS: Of 20581 patients seen, 8029 (39%) had at least one blood draw for CD4 count. Among pre-ART patients, 2668/2844 (93.8%) had CD4 counts performed for eligibility. Of all CD4 samples sent, 8082/9207 (89%) samples were successfully processed. Of those, mean time to processing was 1.6 days (s.d 1.5) but mean time to results being available to clinician was 9.3 days (s.d. 3.7). Regarding HIVRNA, 172 patients of 17737 on ART had a blood draw and only 118/213 (55%) samples were successfully processed. Mean processing time was 39.5 days (s.d. 21.7); mean time to results being available to clinician was 43.1 days (s.d. 25.1). During the one-year evaluated, there were multiple lapses in processing HIVRNA samples for up to 2 months. CONCLUSIONS: Clinicians underutilize CD4 and HIVRNA as monitoring tools in HIV care. Laboratory processing failures and turnaround times are unacceptably high for viral load analysis. Alternative strategies need to be considered in order to meet laboratory monitoring needs.
BACKGROUND: The 2011 Malawi HIV guidelines promote CD4 monitoring for pre-ART assessment and considering HIVRNA monitoring for ART response assessment, while some clinics used CD4 for both. We assessed clinical ordering practices as compared to guidelines, and determined whether the samples were successfully and promptly processed. METHODS: We conducted a retrospective review of all patients seen in from August 2010 through July 2011,, in two urban HIV-care clinics that utilized 6-monthly CD4 monitoring regardless of ART status. We calculated the percentage of patients on whom clinicians ordered CD4 or HIVRNA analysis. For all samples sent, we determined rates of successful lab-processing, and mean time to returned results. RESULTS: Of 20581 patients seen, 8029 (39%) had at least one blood draw for CD4 count. Among pre-ART patients, 2668/2844 (93.8%) had CD4 counts performed for eligibility. Of all CD4 samples sent, 8082/9207 (89%) samples were successfully processed. Of those, mean time to processing was 1.6 days (s.d 1.5) but mean time to results being available to clinician was 9.3 days (s.d. 3.7). Regarding HIVRNA, 172 patients of 17737 on ART had a blood draw and only 118/213 (55%) samples were successfully processed. Mean processing time was 39.5 days (s.d. 21.7); mean time to results being available to clinician was 43.1 days (s.d. 25.1). During the one-year evaluated, there were multiple lapses in processing HIVRNA samples for up to 2 months. CONCLUSIONS: Clinicians underutilize CD4 and HIVRNA as monitoring tools in HIV care. Laboratory processing failures and turnaround times are unacceptably high for viral load analysis. Alternative strategies need to be considered in order to meet laboratory monitoring needs.
Authors: Nellie Wadonda-Kabondo; Diane Bennett; Joep J van Oosterhout; Kundai Moyo; Mina Hosseinipour; Josh Devos; Zhiyong Zhou; John Aberle-Grasse; Thomas R Warne; Clement Mtika; Ben Chilima; Richard Banda; Olesi Pasulani; Carol Porter; Sam Phiri; Andreas Jahn; Debbie Kamwendo; Michael R Jordan; Storn Kabuluzi; Frank Chimbwandira; Mathew Kagoli; Blackson Matatiyo; Austin Demby; Chunfu Yang Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Steven J Reynolds; Gertrude Nakigozi; Kevin Newell; Anthony Ndyanabo; Ronald Galiwongo; Iga Boaz; Thomas C Quinn; Ron Gray; Maria Wawer; David Serwadda Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Beth Rachlis; Giorgos Bakoyannis; Philippa Easterbrook; Becky Genberg; Ronald Scott Braithwaite; Craig R Cohen; Elizabeth A Bukusi; Andrew Kambugu; Mwebesa Bosco Bwana; Geoffrey R Somi; Elvin H Geng; Beverly Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Paula Braitstein Journal: PLoS One Date: 2016-08-10 Impact factor: 3.240